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Structure and dynamics of a 
constitutively active neurotensin 
receptor
Brian E. Krumm1,†, Sangbae Lee2, Supriyo Bhattacharya2, Istvan Botos3, Courtney F. White1, 
Haijuan Du1, Nagarajan Vaidehi2 & Reinhard Grisshammer1
Many G protein-coupled receptors show constitutive activity, resulting in the production of a second 
messenger in the absence of an agonist; and naturally occurring constitutively active mutations in 
receptors have been implicated in diseases. To gain insight into mechanistic aspects of constitutive 
activity, we report here the 3.3 Å crystal structure of a constitutively active, agonist-bound neurotensin 
receptor (NTSR1) and molecular dynamics simulations of agonist-occupied and ligand-free receptor. 
Comparison with the structure of a NTSR1 variant that has little constitutive activity reveals uncoupling 
of the ligand-binding domain from conserved connector residues, that effect conformational changes 
during GPCR activation. Furthermore, molecular dynamics simulations show strong contacts between 
connector residue side chains and increased flexibility at the intracellular receptor face as features 
that coincide with robust signalling in cells. The loss of correlation between the binding pocket and 
conserved connector residues, combined with altered receptor dynamics, possibly explains the reduced 
neurotensin efficacy in the constitutively active NTSR1 and a facilitated initial engagement with G 
protein in the absence of agonist.
G protein-coupled receptors (GPCRs) are highly dynamic and versatile signalling molecules that mediate second 
messenger responses within the cell. Binding of an extracellular agonist causes conformational changes in the 
receptor, triggering activation of signalling partners such as G proteins or arrestin molecules on the intracellu-
lar side of the membrane. Advances in the structural biology of GPCRs have yielded high-resolution structural 
snapshots of inactive1, active-intermediate2,3 and active receptor conformations4–10 and have provided insight into 
the activation mechanism likely shared by class A GPCRs4,5,7,9–11. Subtle, agonist-specific changes in the recep-
tor agonist-binding pocket lead to rearrangement in the packing of connector residues in the receptor centre, 
effecting larger conformational changes on the intracellular side of the GPCR such as the outward movement of 
transmembrane helix (TM) 6.
Constitutive (basal) activity is defined as ligand independent activity, resulting in the production of a second 
messenger in the absence of an agonist. Many wild-type GPCRs have been found to be constitutively active, 
but also mutations in any part of the receptor can cause constitutive activation (constitutively active mutants)12. 
The extent of the basal activity of GPCRs varies and the addition of an agonist may or may not increase the 
signalling response above the basal level. Constitutively active mutants have been linked to human disease13. 
For example, certain mutations in the thyrotropin receptor are associated with hyperthyroidism, mutations in 
the visual pigment rhodopsin cause night blindness and retinitis pigmentosa, and mutations in the parathyroid 
hormone receptor result in skeletal deformations. While the pharmacological and pathological properties of con-
stitutively active receptors have been studied extensively13, the structural basis of constitutive activity remains 
largely unexplored.
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Our research focuses on the neurotensin receptor 1 (NTSR1, ref. 14). Its endogenous agonist ligand neu-
rotensin (NTS) is a 13-amino acid peptide that acts as a neurotransmitter and a hormone in peripheral tissues 
and the nervous system15. NTS displays a wide range of biological activities with important aspects in cancer 
cell growth and the pathogenesis of schizophrenia16,17. Previously, we reported the structure of a thermostable 
mutant, NTSR1-GW5 (ref. 3) bound to the C-terminal portion (NTS8-13) of neurotensin in an active-intermediate 
conformation with six thermostabilizing mutations providing insight into the binding mode of a peptide agonist. 
Agonist-occupied NTSR1-GW5 was unable to activate nucleotide exchange in G proteins, indicating that the 
mutations restricted NTSR1 to relate NTS binding to G protein activation. Subsequent analysis of the effect of the 
mutations resulted in the triple revertant NTSR1-ELF, which was able to stimulate nucleotide exchange at Gαq in 
response to NTS to almost wild-type level18.
Here we report the crystal structure of the constitutively active NTSR1-EL mutant in complex with NTS8-13 
at 3.3 Å resolution, and the pharmacological and dynamic behaviour of the receptor. NTSR1-EL is an 
active-intermediate receptor with a sequence that is almost identical to NTSR1-ELF except that it contains the 
F358A mutation. NTSR1-EL displays pronounced constitutive activity, while NTSR1-ELF does not. As found 
with other constitutively active GPCRs, NTS-induced activation of G protein is reduced in NTSR1-EL, in contrast 
to NTSR1-ELF and the wild-type receptor (NTSR1-WT). Comparison of the crystal structures of NTSR1-EL 
and NTSR1-ELF18 and molecular dynamics (MD) simulations show that structural rearrangements within 
NTSR1-EL, combined with altered receptor dynamics, may facilitate the initial contact with G protein in the 
absence of agonist, while the loss of correlated coupling between the binding pocket and connector residues may 
explain the reduced effect of NTS on signalling.
Results
We describe below the structure, pharmacology and molecular dynamics of the constitutively active mutant 
NTSR1-EL to answer two fundamental questions: What are the features of NTSR1-EL promoting constitutive 
activity; and why is NTS not effective in stimulating a signalling response to the level of the wild-type receptor.
Receptor signalling relies on the communication between the agonist-occupied ligand-binding pocket, the 
connector region, and the G protein-coupling interface of the receptor, linking relatively small conformational 
changes within the ligand-binding site and the connector region to large changes at the intracellular receptor sur-
face. Although interconnected, the ligand-binding site and the G protein interface show only weak allosteric cou-
pling19–21 and each of the three regions may switch individually between multiple distinct conformations20. We 
therefore discuss the structural rearrangements in these regions, but we do not provide an exhaustive correlation 
analysis of the ligand-binding pocket, connector and G protein-coupling interface because there are currently no 
crystal structures of NTSR1 in an antagonist-bound inactive-state nor a fully active G protein-bound state avail-
able for comparison, and the microsecond-scale MD simulations of NTSR1 do not allow observing the transition 
from active-intermediate to inactive or fully active conformations.
NTSR1 construct nomenclature. The NTSR1 mutants discussed in this study are described in 
Supplementary Table 1. They are based on NTSR1-GW5, a receptor with six thermostabilizing mutations 
(A86L1.54, E166A3.49, G215AECL2, L310A6.37, F358A7.42 and V360A7.44) (superscripts are the Ballesteros-Weinstein 
numbers22). Reverting three of these mutations resulted in NTSR1-ELF (with E1663.49, L3106.37, and F3587.42) 
(ref. 18). NTSR1-EL contains the wild-type residues E1663.49 and L3106.37, but also has the F358A7.42 mutation, in 
addition to A86L1.54, G215AECL2, and V360A7.44 found in NTSR1-ELF. The W321A6.48 point mutation is indicated 
in the relevant constructs. One other mutant NTSR1 is discussed, NTSR1-TM86V, which was evolved to be more 
thermostable with neurotensin bound by Plückthun’s laboratory23. This mutant harbours 11 mutations and the 
structure has been determined24.
For the structure determination of NTSR1-EL-T4L, we obtained well-diffracting crystals using the chi-
meric T4 lysozyme (T4L, cysteine-free bacteriophage T4 lysozyme with C54T, C97A) approach25, where most 
of intracellular loop (ICL) 3 is replaced by T4L. For pharmacological analyses, the NTSR1 constructs contain the 
wild-type ICL3, not T4L. The identity of the relevant constructs is unambiguously specified in Figures and Tables.
All models derived from MD simulations use the respective mutant name, but have the ‘MD’ subscript to 
distinguish them from receptor models based on crystal structures or constructs used for pharmacological anal-
yses (for example NTSR1-ELMD versus NTSR1-EL). The term NTSR1MD refers collectively to NTSR1-ELMD and 
NTSR1-ELFMD.
The docking models NTSR1-SRdock and NTSR1-NTSdock are based on the crystal structure of active-intermediate 
NTSR1-LF18, modified with the wild-type NTSR1 sequence, and contain the antagonist SR48692 (ref. 26) or 
NTS8-13, respectively, in the ligand-binding pocket.
NTSR1-EL is constitutively active. The current study characterizes the constitutive activity of NTSR1-EL 
towards G proteins; the analysis of arrestin recruitment by NTSR1-EL will be subject of a separate study.
NTSR1-EL causes in HEK293T cells inositol phosphate (IP) levels to increase over time in the absence of 
ligand (Fig. 1). Such a time-dependent increase in IP concentration is greatly reduced with the wild-type recep-
tor27 or NTSR1-ELF (Fig. 1). Furthermore, the IP response of NTSR1-EL is almost as large in the absence of 
ligand compared to saturating concentrations of NTS (Fig. 1). The latter may be underestimated because the 
constitutive activity of the mutant receptor possibly diminishes the calcium stores of the cells over time. However, 
NTSR1-EL also activates G protein in response to saturating concentrations of NTS to a much lesser degree than 
NTSR1-ELF or wild-type NTSR1 in nucleotide exchange experiments using urea-washed insect cell membranes 
(Supplementary Table 2), an experimental system that assesses the direct interaction of receptor with G protein as 
opposed to the secondary messenger read-out in intact cells.
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For constitutively active mutants, a linear increase of second messenger production is expected with increas-
ing receptor expression levels13. As pcDNA3 plasmids carry the SV40 origin, they can replicate in HEK293T cells, 
which harbour the large T antigen, and thus receptor expression levels are more difficult to control. In addition, 
different receptor mutants might result in different production levels owing to their specific folding properties 
and stabilities. We estimated that a receptor density of ∼ 100,000 receptors/cell leads to maximum IP stimulation 
at saturating concentrations of NTS in HEK293 cells without the large T antigen (Supplementary Fig. 1). Except 
for NTSR1-Y324A, the NTSR1 mutant expression levels are greater than those of NTSR1-WT in transiently 
transfected HEK293T cells (Supplementary Table 3). This excess can thus be considered spare receptors not par-
ticipating in the signalling event.
The ligand binding properties of NTSR1-EL are given in Supplementary Fig. 2 and Supplementary Table 4.
Architecture of NTSR1-EL. To understand the structural implications of constitutive activity, we 
determined the structure of NTSR1-EL to 3.3 Å resolution (Supplementary Table 5, Supplementary Fig. 3). 
Superposition of NTSR1-EL with NTSR1-ELF reveals that it is similar to this structure (root mean square devi-
ation with a value of 0.6 Å for Cα atoms, excluding T4 lysozyme) indicating an active-intermediate NTSR1 con-
formation (Fig. 2). The amino (N) terminus of NTSR1-EL extends, compared to NTSR1-ELF, to residue T43N 
and adopts an unstructured loop that is secured in part by symmetry related molecules. The N-terminus is folded 
back onto extracellular loop (ECL) 2 promoting van der Waals interactions between P51N and the side chains of 
A215ECL2, D216ECL2, and H219ECL2. Electrostatic interactions are also seen between the T43N main chain nitro-
gen and the acidic side chain of D216ECL2. Compared to NTSR1-ELF, the loop connecting the ECL2 β-strands 
has shifted outwards at D216ECL2. However, the significance of this observation remains to be established as the 
position of ECL2 is related to that of the N-terminus, and residues in both the N-terminus and ECL2 are involved 
in crystal contacts. Compared to NTSR1-ELF, the extracellular end of TM5 of NTSR1-EL is 0.6 Å closer to TM6 
when measuring the distances between the Cα positions of T2315.33 and C3326.59. In addition, the outer tip of 
TM7 and ECL3 of NTSR1-EL is shifted outwards compared to NTSR1-ELF. On the intracellular side, the ends of 
most TM segments (TM1-TM3, TM5-TM6) position differently compared to NTSR1-ELF (Fig. 2). In particular, 
TM5 shows an outward placement away from the receptor core when comparing the V2685.69 Cα atom distances 
of NTSR1-EL and NTSR1-ELF (3.9 Å). TM6 displays an even further outward position when comparing the 
V3006.27 Cα atoms (7.4 Å). The end of TM3 has moved slightly towards the receptor core, which affects the posi-
tion of ICL2. TM7 of NTSR1-EL terminates at V3727.56, thus lacking the unstructured region between TM7 and 
H8, seen in NTSR1-ELF, and lacking helix 8.
The rotamer position of W3216.48, a highly conserved amino acid in class A GPCRs within the CWxP motif, 
is dictated by the presence or absence of the F3587.42 side chain. In NTSR1-ELF with F3587.42, the W3216.48 side 
chain is oriented parallel to the lipid bilayer18, whereas in NTSR1-EL with the F358A7.42 mutation, the W3216.48 
side chain is oriented perpendicular to the membrane (Supplementary Fig. 4). The same was observed for 
NTSR1-GW5 (ref. 3) and NTSR1-TM86V-ΔIC3A, which has the F358V7.42 mutation24.
In NTSR1-ELF, we identified L3106.37 as being central to the positioning of the R1673.50 side chain such as to 
allow a bona fide productive interaction with the G protein18. In NTSR1-EL, both L3106.37 and R1673.50 side chains 
are disordered lacking electron density, and so is the E1663.49 side chain of the ERY motif.
Figure 1. Constitutive activity of NTSR1-EL. HEK293T cells were transfected with the respective NTSR1 
constructs, or with the pcDNA3 plasmid as control. The IP production was recorded using the IP-One HTRF 
kit. (a) Data of constitutive receptor activity assays were normalized for each construct to 100% of the respective 
value at t = 0 min, and are presented as the inverse of the normalized signal ratio of 665 nm/620 nm. n, number 
of independent experiments conducted in quadruplicates. NTSR1-WT n = 9 (blue); NTSR1-EL n = 4 (green); 
NTSR1-ELF n = 6 (magenta); control n = 8 (black). Error bars correspond to s.e.m. (b) Agonist-stimulated IP 
accumulation. Data within each set of dose-response assays were normalized to the largest (100%) and smallest 
(0%) average value of the respective wild-type dose-response curve, and analysed by nonlinear regression 
using the GraphPad Prism three-parameter dose-response equation. Data are presented as the inverse of the 
normalized signal ratio of 665 nm/620 nm. n, number of independent experiments conducted in triplicates: 
NTSR1-WT n = 5 (blue); NTSR1-EL n = 4 (green); NTSR1-ELF n = 4 (magenta); NTSR1-TM86V n = 4 (grey); 
control n = 4 (black). Error bars correspond to s.e.m.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:38564 | DOI: 10.1038/srep38564
Subtle, yet distinct differences exist in the NTS8-13 binding mode. The movement of TM5 allows the R9 side 
chain of NTS to engage in a hydrogen bond with T2315.32 (Supplementary Table 6) that is absent in NTSR1-ELF. 
Lacking in NTSR1-EL, but seen in NTSR1-ELF, are hydrogen bond interactions between the NTS carboxylate of 
L13 and Y3517.35 and R3286.55. Instead, the NTSR1-EL R3286.55 engages in a hydrogen bond contact with N2415.42, 
which is not seen in NTSR1-ELF (Supplementary Fig. 5). Whether the carboxylate of L13 of NTS in NTSR1-EL 
forms a water-mediated interaction with R3286.55 cannot be ascertained at a resolution of 3.3 Å.
The hydrophobic cascade. We previously identified in NTSR1-ELF a network of interactions, which we 
term the hydrophobic cascade, between the NTS binding pocket and the connector. The hydrophobic cascade 
consists of the residues Y3246.51, F3587.42, W3216.48 and F3176.44, whose side chains are in van der Waals contact 
with each other in NTSR1-ELF (ref. 18). This network is severed in NTSR1-EL owing to the F358A7.42 thermosta-
bilizing mutation and concurring perpendicular side chain orientation of W3216.48 (Supplementary Fig. 4). As the 
signalling efficacy of NTS is reduced in NTSR1-EL (Supplementary Table 2), one might speculate that the packing 
arrangement within the hydrophobic cascade contributes to the communication between the ligand-binding 
pocket and the connector. In the absence of an inactive, antagonist-bound NTSR1 crystal structure, we performed 
computer-aided docking of the antagonist SR48692 into the binding pocket of the active-intermediate receptor 
(NTSR1-SRdock) (Fig. 3) to explore the effect on potential structural rearrangements. For comparison, the model 
NTSR1-NTSdock with NTS8-13 bound was generated.
Of significance are the side chain orientations of Y3246.51 and F3587.42 in the NTSR1-SRdock model (Fig. 3). In 
the agonist-bound receptor (NTSR1-ELF crystal structure and NTSR1-NTSdock), Y3246.51, F3587.42 and W3216.48 
form mutual π stacking interactions. In NTSR1-SRdock, Y3246.51 moves away from TM7 to allow the π-π inter-
action and hydrogen bond formation with SR48692, thereby disrupting the interaction with F3587.42 seen in the 
agonist-occupied NTSR1. This causes the π stacking between F3587.42 and W3216.48 to be disrupted resulting in 
increased mobility of the F3587.42 side chain (Fig. 3). W3216.48 in turn adopts a side chain orientation perpen-
dicular to the plane of the lipid bilayer. The changed positions of the hydrophobic cascade residues lead to the 
relocation of the extracellular ends of TM6 and TM7 and a closing of the binding pocket by ECL3. Although the 
SR48692 docking model presented here is based on an active-intermediate neurotensin receptor crystal structure, 
it highlights the response of the hydrophobic cascade to different ligands in the binding pocket.
The Y324A6.51 mutation yields receptors that show no measurable [3H]SR48692 binding28 in accordance with 
the role of Y3246.51 in antagonist binding (Fig. 3). The affinity for NTS is not affected in the Y324A6.51 mutant28. 
However, the agonist potency appears reduced in IP assays (Supplementary Table 2). Note that the expres-
sion level of NTSR1-Y324A is half of that of NTSR1-WT (Supplementary Table 3), and therefore a left-shift 
of the dose-response curve may occur if the expression level of the mutant would be higher. The W321A6.48 
mutation in wild type or mutant background also causes only moderate effects on NTS-mediated signalling 
(Supplementary Table 2). The absence of a strong impact of the Y324A6.51 and W321A6.48 single mutations on 
receptor function thus suggests that other transmission links may contribute to the communication between 
the ligand-binding pocket and the connector in addition to the hydrophobic cascade residues, and that the 
Figure 2. Overview of the NTSR1-EL-T4L structure. (a) Side view of NTSR1-EL-T4L in cartoon representation. 
NTSR1-EL is coloured in grey and T4L in pale yellow. Residues of the hydrophobic cascade (Y3246.51, F3587.42, 
W3216.48, F3176.44, bracket) and the connector region (A1573.40, P2495.50, F3176.44, arrow) are shown as red spheres. 
NTS8-13 is depicted as a stick model (orange). (b) Extracellular view. Arrows indicate shifts of TM5, ECL2 and ECL3 
in NTSR1-EL-T4L (grey) compared to NTSR1-ELF-T4L (ref. 18) (green). NTS8-13 has been omitted for clarity. 
(c) Intracellular view. Arrows indicate the position shift of the intracellular ends of TM3, TM5, TM6 and ICL2 of 
NTSR1-EL-T4L (grey) compared to NTSR1-ELF-T4L (green).
www.nature.com/scientificreports/
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hydrophobic cascade residues function in parallel, and not in a sequential ‘domino brick’ manner, in the overall 
allosteric network that effects the conformational changes during the activation process29.
The connector region. The propagation of structural changes in the agonist-occupied binding pocket to the 
cytoplasmic surface is thought to involve an extensive network of polar interactions5 (not discussed here), and 
conserved residues in the receptor centre, whose packing interactions relate to receptor activation. This region is 
referred to as the conserved core triad5, hydrophobic core11 or connector20,30. Strong packing interactions between 
I3.40, P5.50, and F6.44 are observed in both the μ-opioid receptor (μOR)5 and the β2-adrenergic receptor (β2AR)5,8, 
whereas the packing interactions appear to be reduced in the muscarinic M2 receptor (M2R) with the smaller 
V1113.40 forming weaker contacts to F3966.44 and P1985.50 (ref. 7). The corresponding residues in NTSR1 are 
A1573.40, P2495.50, and F3176.44. The conserved residue at position 3.40 is large and hydrophobic in over 70% of 
all class A GPCRs11. However, in NTSR1 it is an alanine (A1573.40) with a much smaller side chain than that of an 
isoleucine in the β2AR and μOR. Consequently, one would anticipate more subtle connector packing differences 
between NTSR1 conformational states compared to β2AR or μOR. The connector regions of the NTSR1-EL and 
NTSR1-ELF crystal structures are, as expected, similar, despite the efficacy differences of NTS for both constructs 
(Fig. 1). However, we note in NTSR1-EL weak van der Waals contacts between the CE1 and CZ atoms of F3176.44 
and the CA and CB atoms of A1573.40, whereas no such interactions are found between F3176.44 and A1573.40 in the 
active-intermediate NTSR1-ELF structure. In addition, TM3 of NTSR1-EL is slightly shifted towards the receptor 
centre (Supplementary Fig. 6).
The rotamer orientation of the W3216.48 side chain in the active-intermediate NTSR1 crystal structures 
impacts upon the distance between TM3 and TM6 within the connector (Supplementary Table 7). The perpen-
dicular orientation of W3216.48 allows tighter packing (reduced distance, NTSR1-EL and NTSR1-GW5), whereas 
the parallel orientation keeps TM3 and TM6 further apart (NTSR1-ELF and NTSR1-LF). However, this effect is 
less pronounced for NTSR1MD (Supplementary Table 8).
In the crystal structures of active-intermediate NTSR1 (refs. 3 and 18) and TM86V-ΔIC3A24, the packing 
interactions between the P2495.50-A1573.40 and A1573.40-F3176.44 side chains show comparatively small changes. 
This is in contrast to the distance between the F3176.44 and P2495.50 side chains, with TM86V-ΔIC3A displaying 
the largest distance among the various NTSR1 constructs (Supplementary Table 9). TM86V-ΔIC3A is a NTSR1 
mutant that adopts an apparent inactive receptor conformation at the inner side in the crystal structure24, but it 
Figure 3. Antagonist docking. (a) The predicted binding pocket of the antagonist SR48692 in the NTSR1-
SRdock model along with the residues within 4 Å of the ligand are shown. The residues highlighted in green 
have been experimentally implicated in SR48692 binding28. Red dashed lines indicate hydrogen bonds. The 
predicted binding pose of SR48692 is qualitatively similar to a model proposed previously28. However, in our 
work, the antagonist is located deeper in the binding pocket compared to the model by Labbé-Jullié. The key 
polar interactions of SR48692 with neurotensin receptor are hydrogen bonds between its carboxylic group and 
R3276.54 and Y3477.31. Mutating R3276.54 to methionine abolishes SR48692 (and NTS) binding, whereas the 
Y347A7.31 mutation results in loss of agonist affinity without affecting antagonist binding28. Y3246.51 and Y3517.35 
form hydrogen bonds with the pyrazole and the amide oxygen of SR48692, respectively. The adamantane ring 
of SR48692 forms hydrophobic contacts with F3316.58 and M208ECL2. Both F3587.42 and Y3597.43 interact with 
the dimethoxyphenyl moiety of SR48692, whereas Y3246.51 engages in π-π stacking with the quinolinyl group 
of the antagonist. (b) Comparison of the side chain orientation of residues Y3246.51, W3216.48, and F3587.42 in 
the agonist-bound model (NTSR1-NTSdock, green) and antagonist-bound model (NTSR1-SRdock, magenta). 
SR48692 is shown as a stick model in yellow. NTS has been omitted for clarity. (c,d) Side chain rotamer 
distribution of the residue F3587.42 in the agonist and antagonist occupied NTSR1dock models: While F3587.42 
adopts only a few rotamer conformations in NTSR1-NTSdock (c), the rotamer distribution becomes more 
diverse in NTSR1-SRdock (d), indicating the increased mobility of the F358 side chain.
www.nature.com/scientificreports/
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is uncertain whether its connector region represents a fully inactive state. In the NTSR1 crystal structures, the 
inter-residue side chain distance between P2495.50 and F3176.44 is smaller for all active-intermediate neurotensin 
receptors compared to TM86V-ΔIC3A (Supplementary Table 9). Comparison of the distances between F6.44 and 
P5.50 in the crystal structures of inactive and active β2AR, M2R and μOR also indicates closer packing between 
those residues in the active state (Supplementary Table 9).
Crystallization attempts of NTSR1-EL in the absence of NTS8-13 were unsuccessful. Therefore, we used MD 
simulations (the energetics of NTSR1MD are shown in Supplementary Fig. 7 and Supplementary Table 10) to 
analyse the variation of the minimum inter-residue distances between connector residues of NTSR1-ELMD and 
NTSR1-ELFMD in the presence and absence of agonist (Fig. 4).
In the presence of NTS, the packing interactions between P2495.50, A1573.40 and F3176.44 in NTSR1-ELMD 
and NTSR1-ELFMD are similar to that seen in the crystal structures of the agonist-occupied NTSR1-EL 
and NTSR1-ELF. This does not substantially change for NTSR1-ELMD in the absence of NTS. However, the 
NTSR1-ELFMD system shifts to a much larger distance in the absence of agonist (the peaks of the distribution 
for the P2495.50-F3176.44 and A1573.40-F3176.44 distances centre at 7–8 Å rather than 4–5 Å). Thus the connec-
tor region of NTSR1-ELMD appears ‘active’ irrespective of the presence or absence of agonist. This is in con-
trast to NTSR1-ELFMD, where a more compact connector region is only observed in the presence of NTS in the 
ligand-binding pocket. Assuming that closer packing of connector residues is indicative for a more active state 
(Fig. 4), the dynamic behaviour of NTSR1-ELFMD might explain why nucleotide exchange at the G protein occurs 
in response to agonist, but no appreciable constitutive activity is seen in the absence of NTS. In contrast, the 
connector region of NTSR1-ELMD remains packed in the presence and absence of NTS, possibly explaining its 
constitutive activity and the reduced effect of NTS on signalling.
Dynamics of W3216.48 and F3176.44. Spectroscopic evidence suggested changes in the environment of 
W6.48 upon rhodopsin activation31,32. However, a rotamer change of W6.48 was not observed in any crystal struc-
ture of active GPCRs5,7–9,33, but only found in the structures of active-intermediate NTSR1-ELF and NTSR1-LF18. 
MD simulations based on the active μOR structure5 suggested that W6.48 serves as a link between the ligand bind-
ing pocket and the connector region.
Crystallography typically captures the lowest energy state within an ensemble of conformations (here 
active-intermediate) that may subtly differ from other signalling conformations of membrane-inserted recep-
tors, not observed in crystal structures21. Therefore, we studied the dynamic behaviour of W3216.48 and F3176.44 
by MD simulations. The χ2 angles of W3216.48 of NTS-occupied NTSR1-ELFMD and NTSR1-ELMD stay close 
to the respective angles in the corresponding crystal structures (Fig. 5). In contrast, the W3216.48 side chain 
becomes more dynamic in the absence of agonist, adopting perpendicular and parallel rotamer orientations in 
NTSR1-ELMD, and tilting even further towards the intracellular receptor side in NTSR1-ELFMD (χ2 angle of −25°). 
This is accompanied by a change of the F3176.44 side chain orientation to avoid steric hindrance, as the ben-
zene moiety of the W3216.48 indol ring would come too close to the phenyl side chain of F3176.44 as seen in the 
NTSR1-ELF and NTSR1-EL crystal structures (χ1 torsional angles of −163° and −171°, respectively). The change 
of the F3176.44 side chain position (χ1 angle change from −163° to −60°) would resolve the clash (Fig. 5).
In addition, the mobility of the F3176.44 side chain appears also to be an inherent property, and not solely 
determined by the rotamer orientation of W3216.48, as F3176.44 adopts side chain positions with χ1 angles ranging 
Figure 4. Packing of connector residues during MD simulations. Minimum inter-residue distances between 
any pair of the side chain atoms (excluding hydrogen atoms) of A1573.40, P2495.50 and F3176.44 were measured 
over the entire MD trajectories for NTSR1-ELFMD (top) and NTSR1-ELMD (bottom) ensembles in the presence 
of NTS (solid curves) and absence of ligand (dashed curves). The vertical lines represent the minimum inter-
residue side chain distances in the NTSR1-EL-T4L (PDB code 5T04, blue), NTSR1-ELF-T4L (PDB code 4XEE, 
black) and TM86V-ΔIC3A (PDB code 3ZEV, red) crystal structures.
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from −90° to −60°, when the W3216.48 side chain is oriented parallel (agonist-occupied NTSR1-ELFMD, χ2 angle 
of 55°) and perpendicular (NTSR1-ELMD without NTS, χ2 angle of 120°).
Conformational dynamics of the G protein coupling interface. Activation of the G protein by an 
agonist-occupied receptor or by a constitutively active receptor mutant requires an initial docking step of the G 
protein, which may be facilitated by a more open cleft and higher flexibility within the intracellular face of the 
receptor.
The structure of agonist-bound NTSR1-EL appears more open at the intracellular side than that of NTSR1-ELF 
(Fig. 2), suggesting easier accommodation of the C-terminus of a Gα subunit, yet the efficacy of NTS in IP assays 
is less than that for NTSR1-ELF (Fig. 1). However, the distance between residues N2575.58 and Y3697.53, whose 
interaction was implied to stabilize the active receptor conformation7, is larger in the NTSR1-EL crystal struc-
ture compared to NTSR1-ELF (Supplementary Table 11), suggesting possibly a less active-intermediate state for 
NTSR1-EL, in agreement with the pharmacology of the respective mutants. As crystal structures of NTSR1 in 
complex with G protein are currently unavailable for comparison, we used MD simulations to assess the receptor 
dynamics at the G protein interface.
We compared ensembles of conformations of NTSR1MD, with and without NTS, using distance measure-
ments between TM3-TM6 (distance between Cα atoms of R1673.50-L3036.30) and TM3-TM7 (distance between 
Cα atoms of R1673.50-Y3697.53) (Fig. 6). An increase in the distance between TM3 and TM6, and a decrease 
in the distance between TM3 and TM7, is observed in the active state structures of other class A GPCRs (for 
example ref. 9). Thus the distance measurements between TM3-TM6 and TM3-TM7 may serve as one of the 
indicators for the activation state of the receptor. The ensemble clusters show two distinct populations (which 
we call ‘less’ active-intermediate and ‘more’ active-intermediate) for NTSR1-ELFMD in the presence of agonist, 
whereas NTSR1-ELMD displays a more homogenous single ensemble in the presence of the peptide (Fig. 6). 
Analysis of the population density distribution of the TM3-TM6 and TM3-TM7 distances in the absence of ago-
nist shows reduced heterogeneity for NTSR1-ELFMD. For NTSR1-ELMD, the differences between NTS-loaded and 
agonist-free population distributions are small with the ensembles (both with and without ligand) being ‘more’ 
active-intermediate than those of NTSR1-ELFMD in the absence of agonist. The appearance of distinct popula-
tions for NTSR1-ELFMD in the presence of NTS correlates with multiphasic dose response curves in nucleotide 
exchange assays for NTSR1-ELF, whereas the more homogenous single ensemble of NTSR1-ELMD relates to the 
monophasic behaviour for NTSR1-EL (Supplementary Table 2).
The strength of interhelical interactions relates to the flexibility within the receptor, possibly influencing the 
initial encounter between receptor and G protein. We therefore calculated the hydrogen bond and van der Waals 
contacts in NTSR1MD (Supplementary Table 12). NTSR1-ELFMD shows stronger interhelical packing i.e. more 
interhelical contacts in the absence of NTS within the intracellular receptor half compared to the presence of ago-
nist. The opposite is observed for NTSR1-ELMD where there are fewer interactions i.e. weaker interhelical packing 
in the absence of NTS compared to the presence of agonist. Notably, the location of many interhelical contacts 
Figure 5. Dynamic behavior of the W3216.48 and F3176.44 residues. (a) Hypothetical side chain orientations 
of W3216.48 (χ2 angles of 120°, 40°, 20°, −25°) and F3176.44 (χ1 angles of −90°, −60°) are projected onto the 
NTSR1-EL-T4L crystal structure (orange, W3216.48 χ2 angle of 103°, F3176.44 χ1 angle of −171°). (b) The 
population distribution of the χ2 torsional angles of W3216.48 for NTSR1-ELFMD (top panel) and NTSR1-ELMD 
(bottom panel) over the entire MD trajectory. The vertical lines represent the χ2 angles in the respective crystal 
structures. (c) The population distribution of the χ1 angles of F3176.44 for NTSR1-ELFMD and NTSR1-ELMD. 
The vertical lines represent the χ1 angles in the respective crystal structures. Solid curves are population 
distributions in the presence of agonist, whereas hashed curves are population distributions in the absence of 
agonist.
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within the respective conformational ensembles (NTSR1-ELFMD or NTSR1-ELMD, with and without agonist) is 
different (Fig. 7), although a number of interactions are identical.
The stimulation by NTS of a signalling response is high for NTSR1-ELF, but modest for NTSR1-EL (‘fold stim-
ulation’, see Supplementary Table 2). In contrast, NTSR1-EL signals in the absence of agonist, which NTSR1-ELF 
almost does not (Fig. 1). Overall, the analysis of the conformational dynamics of the G protein interface of 
NTSR1MD suggests higher flexibility (Fig. 7, Supplementary Table 12) and the propensity to adopt ‘more active’ 
active-intermediate states (Fig. 6) as possible parameters for the ability to accommodate the incoming G protein.
Discussion
Constitutively active receptor mutants are thought to adopt spontaneously a conformation able to activate G pro-
tein, possibly by either releasing inactive state constraints and/or forming new interactions that stabilize a more 
active state13, lowering the energy barrier between the inactive and active receptor conformations. Constitutively 
active mutants have been described for many GPCRs34. However, the structural basis of constitutive activity has 
only been investigated for a limited number of rhodopsin mutants targeting the retinal binding pocket33,35 and 
the G protein-binding site36. In the E113Q3.28 rhodopsin mutant structure33, the salt bridge between E1133.28, as 
counter-ion to the protonated Schiff base, and K2967.43 is broken, removing constraints between TM3 and TM7 in 
the inactive state. The G90D2.57 mutation introduces a stabilizing salt bridge to K2967.43, which disfavours covalent 
binding of the retinal ligand and destabilizes the inactive conformation35. The M257Y6.40 mutation stabilizes the 
G protein-binding interface through interactions with residues that are critical for receptor activation (Y3067.53, 
Y2235.58, R1353.50) (ref. 36). Furthermore, the crystal structure of the human cytomegalovirus GPCR US28 in 
complex with fractalkine in an active-intermediate state has been reported37 and MD simulations suggested that 
the agonist-independent activity of US28 may result from amino acid interactions of the DRY motif destabilizing 
the inactive state. The rhodopsin mutants provide examples in which the molecular basis for constitutive activity 
is rather specific36. The explanation of inherent constitutive activity of many other receptors, likely originating 
from an overall increased conformational flexibility, may thus become more complex than that for the rhodopsin 
mutants.
The NTSR1 sequence contains a bulky phenylalanine residue at position 7.42 and a tryptophan residue at posi-
tion 6.48. The combination of F7.42 and W6.48 is also found in the receptors for neuromedin U, motilin and ghrelin, 
Figure 6. Conformational dynamics of the G protein-coupling interface. NTSR1MD snapshots were sampled 
in MD simulations and projected into the distance between TM3 and TM6, and the distance between TM3 and 
TM7. Contour maps of the Cα-Cα distances of R1673.50-L3036.30 and R1673.50-Y3697.53 are shown for NTSR1-
ELFMD and NTSR1-ELMD in the presence of NTS8-13 (upper panels) and absence of ligand (lower panels). 
The conformational clusters are colour coded from blue to red according to their population density for the 
TM3-TM6 and TM3-TM7 distances, with red indicating larger populations in the density distributions. Open 
circles represent the Cα-Cα distances found in the crystal structures of inactive NTSR1 (PDB code 3ZEV, 
black); inactive β2AR (PDB code 2RH1, orange); active β2AR (PDB code 3SN6, red); NTSR1-ELF-T4L (PDB 
code 4XEE, magenta) and NTSR1-EL-T4L (PDB code 5T04, blue). The light orange box indicates ‘more active’ 
distances between TM3-TM6 and TM3 and TM7.
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and NTSR2, but not in other class A GPCRs18. The motilin receptor and wild-type NTSR1 are silent with respect 
to constitutive activity27,38. In contrast, the ghrelin receptor is highly constitutively active and has been extensively 
characterized by pharmacological, mutagenesis and modelling studies29,38,39. Constitutive activity has also been 
ascribed to the single point mutant NTSR1-F358A27, but no crystal structure has been reported for this mutant.
Why is NTSR1-EL constitutively active? The molecular basis for constitutive activity and ligand-based activa-
tion of NTSR1 is expected to be similar as it ultimately results in the binding and activation of G protein in both 
cases. Therefore, the comparison of NTSR1-EL, which signals both in the presence and absence of NTS, with 
NTSR1-ELF, which causes a secondary messenger response only in the presence of agonist (Fig. 1), may point 
to features in the connector region and the intracellular receptor face associated with activation. The connector 
regions of the NTSR1-EL and NTSR1-ELF crystal structures do not show large differences in the overall pack-
ing arrangement, which is perhaps anticipated, as both structures represent active-intermediate conformations. 
However, we observe in MD simulations tight contacts of connector residue side chains in NTSR1-ELMD, irrespec-
tive of the presence or absence of agonist, as is also found in NTS-occupied NTSR1-ELFMD, but not in ligand-free 
NTSR1-ELFMD (Fig. 4). Thus tight interactions within the connector region may describe a conformational ele-
ment attributed to the activation of NTSR1, which correlates with significant IP production of NTSR1-EL without 
and with agonist, and NTSR1-ELF with NTS (Fig. 1). A more open cleft (Fig. 6) and fewer interhelical contacts 
within the intracellular half of the receptor (Fig. 7, Supplementary Table 12) may accelerate the initial contact 
between G protein and NTSR1-ELF in the presence of agonist, and NTSR1-EL irrespective of ligand occupancy.
What are the global changes within the connector region upon activation? Although the crystal structure of 
NTSR1 in its inactive, antagonist-bound state is currently unknown, comparison of the agonist-bound NTSR1-EL 
and TM86V-ΔIC3A structures reveals distinct differences within the connector region (Supplementary Fig. 8). 
TM86V-ΔIC3A is a NTSR1 mutant that has been crystallized in the presence of NTS but adopts an apparent inac-
tive receptor conformation at the inner receptor side24 and does not produce an IP signalling response (Fig. 1). The 
W3216.48 side chain in TM86V-ΔIC3A is positioned upward, like in NTSR1-EL, because of the F358V7.42 muta-
tion. In NTSR1-EL, TM3 is shifted up compared to TM86V-ΔIC3A, and TM3 bulges inwards at T1563.39, V1603.43, 
and S1643.47. TM5 bulges slightly in towards TM3 at P2495.50 and S2455.46 (one turn towards the ligand binding 
pocket) in the NTSR1-EL structure. The counter-clockwise rotation of F3176.44 (viewed from the top) causes the 
distance between the P2495.50–F3176.44 side chains to become smaller in NTSR1-EL (Supplementary Table 9).
What is the role of W3216.48 and the hydrophobic cascade in the signalling process of NTSR1? Although W6.48 
is highly conserved in class A GPCRs, about one fifth of receptors have another aromatic or non-aromatic resi-
due at this position39. Furthermore, mutation of W6.48 to alanine and other residues resulted in strong effects on 
signalling in some receptors, but showed no or little consequence in others. For example, mutation to alanine of 
W6.48 in the ghrelin receptor eliminated constitutive activity and strongly impaired agonist-induced signalling39, 
whereas alanine substitution in NTSR1 has only moderate effects (Supplementary Table 2). These observations 
Figure 7. Interhelical contacts of NTSR1MD. Interhelical hydrogen bond and van der Waals interactions 
that are present in more than 50% of the conformations in the MD trajectories were identified 
(Supplementary Table 12). Spheres represent the Cα atoms of residues engaged in interhelical contacts, 
projected onto the NTSR1-EL-T4L crystal structure. Interactions in the presence and absence of NTS are 
coded in blue and red, respectively, and are shown for NTSR1-ELFMD (left) and NTSR1-ELMD (right). Residues 
marked in magenta are found in both MD simulations (presence and absence of agonist) of NTSR1-ELMD, but 
those residues engage in different contacts. Interhelical contacts that are identical in the MD simulations in the 
presence and absence of agonist for NTSR1-ELFMD and NTSR1-ELMD, respectively, are not shown.
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suggest that the role of W6.48 in the signal transduction mechanism is receptor dependent. In NTSR1, the rotamer 
orientation of the W3216.48 side chain and the integrity or disconnect of the hydrophobic cascade appear to relate 
to agonist sensing. NTS-occupied NTSR1-ELF, which has stacked hydrophobic cascade residues and the W3216.48 
side chain in a parallel orientation, signals almost as strong as the wild-type receptor. In contrast, NTSR1-EL, with 
a perpendicular W3216.48 side chain orientation and a small non-aromatic alanine at position 7.42, shows a strongly 
reduced response above basal in the presence of agonist. The inability of NTS to stimulate a signalling response in 
NTSR1-LF, which has the W3216.48 side chain in a parallel orientation in the crystal structure18, may have its cause 
in the E166A3.49 mutation in the conserved ERY motif. There are no crystal structures of any un-liganded NTSR1 
mutants to examine the W3216.48 side chain orientations, but increased mobility of W3216.48 is observed in MD sim-
ulations in the absence of agonist. In addition, substantial rearrangements and increased dynamics of hydrophobic 
cascade residues are seen in the docking model NTSR1-SRdock with antagonist bound (Fig. 3). Thus it appears that 
NTSR1 communicates the presence of NTS to the connector region by stacking of the hydrophobic cascade residues. 
Severing this link in NTSR1-EL reduces the sensing of bound agonist and thus peptide-induced signalling (Fig. 8).
Methods
NTSR1 constructs. The baculovirus construct NTSR1-EL-T4L used for crystallization consisted of the 
hemagglutinin signal peptide and the Flag tag40, followed by the thermostabilized rat NTSR1 (T43-K396 con-
taining the mutations A86L1.54, G215AECL2, F358A7.42, V360A7.44) with the ICL3 residues H269-E296 replaced by 
the cysteine-free bacteriophage T4 lysozyme (N2-Y161 with the mutations C54T and C97A) and a GSGS linker. 
A deca-histidine tag was placed at the C-terminus. All other constructs used for pharmacological analyses are 
summarized in Supplementary Table 1.
In the Methods sections, we distinguish between NTSR1 constructs containing T4L or the wild-type ICL3 
sequence. In the main text, we use only one name for a particular construct; NTSR1-EL refers interchangeably to 
NTSR1-EL-T4L and NTSR1-EL, the latter containing the wild-type ICL3, not T4L. The identity of the respective 
construct is evident from the context of writing.
Expression of Gq protein in insect cells and purification was done as described18.
Expression of NTSR1 in insect cells was done as described18.
Preparation of urea-washed P2 insect cell membranes was done as described18.
Figure 8. Constitutive and agonist-induced signalling of NTSR1. The cartoons compare ‘activation’ features 
of (a) NTSR1-ELF in the absence of agonist, (b) NTSR1-ELF with NTS, and (c) NTSR1-EL without ligand. The 
schematic, oversimplified representation is based on crystallographic data and MD simulations. Amino acids 
of the hydrophobic cascade and the connector region are shown as solid coloured symbols, and NTS is depicted 
as an orange box. Dashed grey lines indicate the relative number of interhelical contacts within the intracellular 
half of the receptor, and dashed grey arrows indicate side chain mobility. Blue arrows indicate a higher 
propensity of the receptor to accommodate the incoming G protein. The overall structure of the unliganded 
receptor is assumed to be similar, but not identical, to that of the NTS8-13 bound NTRSR1-EL structure because 
the IP response is almost as large in the absence of ligand compared to saturating concentrations of NTS, and 
the dynamic properties of NTSR1-ELMD are similar with and without agonist. A network of amino acid side 
chain interactions constitutes the link between the NTS-occupied binding pocket and the connector region. 
This interaction is disrupted in NTSR1-EL, possibly explaining the diminished signalling potency of NTS. 
The rotamer orientation and dynamics of the conserved W3216.48 side chain affect neighbouring amino acid 
residues, and are relevant to the activation process as this determines the position of transmembrane helices 
and the packing of the connector, implicated in receptor activation. Tightly packed residues of the connector 
and a flexible G protein interface may represent switches in intermediate conformations, facilitating the initial 
interaction with the G protein and explaining the constitutive activity of NTSR1-EL.
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Ligand binding experiments. All radioligand binding assays were conducted as described18 with 
urea-washed P2 insect cell membranes containing the indicated NTSR1 constructs. Independent experiments 
were carried out in single data points.
Data of agonist [3H]NTS ([3,11-tyrosyl-3,5-3 H(N)]-pyroGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg- 
Pro-Tyr-Ile-Leu) (PerkinElmer) saturation binding experiments were analysed by nonlinear regression using the 
GraphPad Prism software and best fit to a one-site binding equation to determine the dissociation constants (Kd). 
Note that the saturation binding experiments using wild-type NTSR1 were conducted at equilibrium. In contrast, 
binding of [3H]NTS to the NTSR1 mutants did not reach equilibrium within the incubation time because of the 
slow agonist off-rates.
Competition assays with the non-peptide antagonist SR48692 (ref. 26) were performed in the presence of 
[3H]NTS. Data were analysed by nonlinear regression with the GraphPad Prism three-parameter dose-response 
equation using the concentrations of total SR48692 added versus bound [3H]NTS. IC50 values were converted into 
Ki values using the Cheng Prusoff equation41.
The effect of Na+ ions on [3H]NTS binding was recorded and data were analysed by nonlinear regression using 
the GraphPad Prism four-parameter dose-response equation (variable slope) with the top and bottom plateau 
constrained from 100–50% (NTSR1-EL-T4L, NTSR1-EL).
The association and dissociation of [3H]NTS was assessed as described18.
GTPγS assays. Prior to G protein coupling assays, the P2 membranes were treated with urea to remove 
peripherally bound membrane proteins42,43. GDP/[35S]GTPγS exchange assays were performed as described18,44,45 
with 1 nM receptor, 140 nM Gq protein, and specified amounts of NTS in the reaction. Experiments were con-
ducted either at saturating ligand concentrations (NTS at 20 μM) or using a range of ligand concentrations for 
dose-response assays (0–20 μM). Independent experiments were carried out in single data points. Data from 
dose-response experiments were fit to an equation with a Hill slope of 1, except when indicated otherwise.
Inositol phosphate determination. HEK293T or HEK293 cells were transiently transfected with 
pcDNA3 or pME-HA (Lucigen) plasmid derivatives (Supplementary Table 1) using the lipofectamine 3000 rea-
gent (Invitrogen). As a control, cells were transfected with the parental pcDNA3 vector.
For inositol phosphate determination, HEK293T or HEK293 cells were seeded the day after transfection in 
white-walled 96 well plates (Thermo Scientific) (100 μl per well; 50,000 cells/well). The next day, IP accumulation 
was measured using the IP-One HTRF kit (Cisbio Bioassays) according to the manufacturer’s instructions. The IP 
One assay is a competitive immunoassay based on an IP1-specific antibody labelled with Lumi4-Tb cryptate. IP1 
produced by cells competes with d2-labeled IP1 for binding to the antibody. Thus the signal is inversely propor-
tional to the level of cellular IP. Cells were stimulated for 60 min at 37 °C with NTS (100 pM – 10 μM) in 70 μl of IP 
stimulation buffer containing LiCl to inhibit the degradation of IP. To probe for constitutive receptor activity, cells 
were incubated for the indicated time points in the absence of ligand. IP1-d2 reagent (15 μl) and an anti-IP1 anti-
body labelled with Lumi4-Tb cryptate (15 μl) were then added to the cells. The mixture was incubated for 1 hour 
at room temperature. Signals at 665 nm and 620 nm were detected using a FlexStation 3 (Molecular Devices) 
fluorescence reader, and values were expressed as the signal ratio of 665 nm / 620 nm. Independent experiments 
were carried out in triplicates (does-response experiments) or quadruplicates (constitutive receptor activity). 
Data within each set of dose-response assays were normalized to the largest (100%) and smallest (0%) average 
value of the respective wild-type dose-response curve, and analysed by nonlinear regression using the GraphPad 
Prism three-parameter dose-response equation. Data are presented in figures as the inverse of the normalized 
signal ratio of 665 nm/620 nm. Data of constitutive receptor activity assays were normalized for each construct 
to 100% of the respective value at t = 0 min. Data are presented in figures as the inverse of the normalized signal 
ratio of 665 nm/620 nm.
To determine the minimum number of receptors saturating the IP response at 10 μM NTS, HEK293 cells were 
transfected with varying amounts of plasmid. The day after, the cells were seeded in white-walled 96 well plates 
(Thermo Scientific) (100 μl per well; 50,000 cells/well, quadruplicates) and in 6 well plates (2 ml per well; 1 × 106 
cells/well, duplicates). The next day, cells in 96 well plates were probed for IP production for 60 min as described 
above. Data in the presence of NTS were normalized for each plasmid concentration to 100% of the respective 
value at t = 0 min. Data are presented in figures as the inverse of the normalized signal ratio of 665 nm/620 nm. 
The cells in the 6 well plates were detached, suspended in PBS, and subjected to radioligand binding analysis at 
10 nM [3H]NTS. The cell density was determined using the Countess II FL automated cell counter (Invitrogen), 
and the receptor number at the cell surface was calculated. The amount of specifically bound [3H]NTS (in dpm) 
in 96 well plates was estimated from the amount of specifically bound [3H]NTS in 6 well plates by dividing this 
number by 20 (1 × 106/50,000).
Purification of NTSR1-EL-T4L. Cells from 3 L of insect cell culture were thawed and the volume was 
brought to approximately 350 ml with hypotonic buffer (10 mM Hepes pH 7.5, 10 mM MgCl2, 20 mM KCl). 
The cells were then resuspended using a Turrax T-25 (IKA) homogenizer at 8,000 rpm for 2 min. After cen-
trifugation (45Ti rotor, 125,000× g, 20 min, 4 °C, Optima L90K, Beckman), the membranes were resuspended 
(Turrax T-25) in approx. 350 ml of high-salt buffer (10 mM Hepes pH 7.5, 1 M NaCl, 10 mM MgCl2, 20 mM 
KCl) supplemented with AEBSF (100 μM), and centrifuged again. The high-salt buffer wash was repeated one 
more time resulting in about 22 gram of wet membrane pellet. All subsequent steps were performed at 4 °C or 
on ice, and AEBSF (100 μM final concentration) was repeatedly added throughout the procedure. The washed 
membranes were resuspended in 187 ml of buffer [75 mM TrisHCl pH 7.4, 45% (v/v) glycerol] containing 15 μM 
NTS8-13 (Arg-Arg-Pro-Tyr-Ile-Leu) and stirred for 30 min to allow agonist binding to membrane-inserted 
NTSR1. The receptor was extracted by drop-wise addition of 93 ml of a 3% (w/v) lauryl maltose neopentyl glycol 
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(2,2-didecylpropane-1,3-bis-β-D-maltopyranoside) (LMNG) (Anatrace)/0.3% (w/v) cholesteryl hemisucci-
nate Tris salt (CHS) (Anatrace) solution. After 2 hours, NaCl was added, and the solution was gently stirred 
for an additional 15 min. The final volume was 280 ml containing 50 mM TrisHCl pH 7.4, 30% (v/v) glycerol, 
200 mM NaCl, 1% (w/v) LMNG/0.1% (w/v) CHS and 10 μM NTS8-13. The sample was clarified by centrifuga-
tion (45Ti rotor, 125,000× g, 1 hour, Optima L90K, Beckman), adjusted with imidazole to a final concentration 
of 20 mM, and batch-incubated overnight with 1.5 ml Talon resin equilibrated with Talon-A+ buffer [50 mM 
TrisHCl pH 7.4, 30% (v/v) glycerol, 200 mM NaCl, 20 mM imidazole, 1 μM NTS8-13, 0.1% (w/v) LMNG/0.01% 
(w/v) CHS]. After washing the resin with 22.5 ml of buffer Talon-A+ and 15 ml of buffer Talon-A2+ [50 mM 
TrisHCl pH 7.4, 30% (v/v) glycerol, 200 mM NaCl, 20 mM imidazole, 1 μM NTS8-13, 0.05% (w/v) LMNG/0.005% 
(w/v) CHS], NTSR1-EL-T4L was eluted in 0.5 ml steps with Talon-B+ buffer [50 mM TrisHCl pH 7.4, 30% (v/v) 
glycerol, 200 mM NaCl, 250 mM imidazole, 10 μM NTS8-13, 0.05% (w/v) LMNG/0.005% (w/v) CHS]. Peak frac-
tions were collected (2.5 ml) and desalted using a PD10 column equilibrated in PD10 buffer [50 mM TrisHCl 
pH 7.4, 200 mM NaCl, 0.003% (w/v) LMNG/0.0003% (w/v) CHS]. NTS8-13 was then added to a concentration of 
20 μM, and the sample was used for crystallization. Three liters of insect cell culture yielded ~3.3 mg of purified 
NTSR1-EL-T4L.
Stability tests in detergent solution. The stability of NTSR1 was measured in the presence of LMNG/
CHS in the +NTS format45 as described18. Control reactions on ice were recorded at the start and at the end of 
each denaturation experiment. The percentage of activity remaining after heat exposure was determined with 
respect to the unheated control. Data were analysed by nonlinear regression using a Boltzmann sigmoidal equa-
tion in the Prism software (GraphPad).
Crystallization. Purified desalted NTSR1-EL-T4L was adjusted to 100 μM Tris (2-carboxyethyl) phosphine 
hydrochloride (TCEP) and 350 μM NTS8-13 and concentrated to an estimated 60 mg ml−1 using a 100,000 MWCO 
concentrator (Amicon Ultra, Millipore). After addition of NTS8-13 to 1.5 mM and centrifugation (TLA 120.1 
rotor, 128,000× g, 30 min, 4 °C, Beckman), the sample was mixed with 1.5 parts by weight of a mix of monoolein 
with cholesterol (10:1) using the two-syringe method46. The resulting lipidic cubic phase47 mix was dispensed in 
60–70 nl drops onto Laminex plates (Molecular Dimensions) and overlaid with 825 nl precipitant solution using a 
Mosquito LCP robot (TTP Labtech). Crystals of NTSR1-EL-T4L grew at 20 °C after 3 days in precipitant solution 
consisting of 13–16% (v/v) PEG 400, 80 mM TrisHCl pH 8.5–9.0, 1.9 mM TCEP, 68–91 mM lithium acetate and 
0.9 mM NTS8-13. Crystals were harvested directly from LCP using micro-loops (MiTeGen) and immediately flash 
frozen in liquid nitrogen without adding extra cryoprotectant.
Data collection and structure determination. Data collection was performed using the JBluIce-EPICS 
data acquisition software at the GM/CA-CAT (23-ID-B and 23-ID-D) beamlines at the Advanced Photon Source 
of the Argonne National Laboratory using a 10–20 μm minibeam at a wavelength of 1.0332 Å. Crystals within the 
loops were located by diffraction using the automated rastering module of JBluIce-EPICS48,49. Partial data sets 
(wedges of 5–10 degrees) were collected from crystals exposed to the non-attenuated minibeam for 1–2 sec and 1 
degree oscillation (23-ID-B), or 0.3 sec and 0.3 degree oscillation (23-ID-D) per exposure.
For NTSR1-EL-T4L, a 97.3% complete data set at 3.3 Å resolution was obtained by indexing, integrating, scal-
ing, and merging partial data sets from 13 crystals using XDS50, and Aimless51 of the CCP4 Suite52.
Structure determination was performed by molecular replacement using the Phaser module of the CCP4 
Suite. Two search models were created using the structure of NTSR1-ELF-T4L (PDB code 4XEE) with one con-
taining the T4 lysozyme domain and one containing the receptor seven-helix bundle. One copy of each search 
model was found, producing a single solution. Subsequent refinement was performed using the MR solution 
with rounds of PHENIX.AutoBuild53 and PHENIX.Rosetta_Refine followed by PHENIX.Refine with simulated 
annealing, and Refmac5 using translation, libration and screw-rotation (TLS) parameters54. TLS displacement 
groups used in the refinement were defined by the TLSMD server55. Manual examination and rebuilding of 
refined coordinates was accomplished using COOT56. The NTSR1-EL-T4L structure was refined with final R/
Rfree values of 25.3/28.3. The quality of the model was checked using the Molprobity server57. The Ramachandran 
statistics for NTSR1-EL-T4L are: 98.5% favoured regions, 1.5% allowed regions, 0% outliers. The signal to noise 
ratio of I/σ(I) was ≥ 2.0 at 3.4 Å for NTSR1-EL-T4L. A summary of data collection and refinement statistics is 
reported in Supplementary Table 5. A stereo figure of representative electron density for TM7 of NTSR1-EL-T4L 
is given in Supplementary Fig. 3.
For NTSR1-EL-T4L, initial crystal screening was done at the Stanford Synchrotron Radiation Lightsource, 
beamline 12-2.
Figures were prepared in PyMOL (Schrödinger). Structural alignments were done with the ‘align’ command 
of PyMOL.
Docking of SR48692 into the ligand binding pocket of NTSR1. The neurotensin agonist was 
removed from the crystal structure of NTSR1-LF (A86L1.54, E166A3.49, G215AECL2, V360A7.44) (PDB code 4XES) 
(ref. 18), and the side chains of L861.54, A1663.49, A215ECL2, and A3607.44 were changed to their respective wild-type 
amino acids (A861.54, E1663.49, G215ECL2, V3607.44). The proposed SR48692 binding site28, based on mutagenesis 
data for orienting the antagonist, is partially occluded by the side chains of the residues Y1463.29, R1493.32, R3286.55 
and Y3246.51 in the NTSR1-LF crystal structure. These residues were thus changed to alanine prior to docking the 
ligand.
The partial charges of the SR48692 ligand atoms were calculated based on electrostatic potential using Jaguar 
(Schrödinger Inc.). Using these charges, 60 distinct ligand conformations were generated outside the receptor 
using the program Macromodel (Schrödinger Inc.). These antagonist conformations were docked into NTSR1 
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using GlideXP (Schrödinger Inc.) imposing two experimentally derived constraints28; a salt bridge between 
R3276.54 and the carboxylic acid moiety of the antagonist, and the criteria that the dimethoxyphenyl moiety of 
SR48692 is within 4.5 Å of F3587.42. The docked conformations that satisfied these two distance constraints were 
further filtered using favorable contacts with the experimentally implicated residues M208ECL2, F3316.58, Y3517.35, 
F3587.42 and Y3597.43 (ref. 28). Finally, the side chains of A1463.29, A1493.32, A3286.55 and A3246.51 were mutated 
back to their wild type forms. Then the side chain rotamer conformations of all residues within 5 Å of SR48692 
were optimized using Prime (Schrödinger Inc.), followed by minimization of the potential energy of the entire 
receptor-ligand complex using Macromodel (Schrödinger Inc.). The resulting model is called NTSR1-SRdock.
For comparison, the model NTSR1-NTSdock was generated from the crystal structure of NTSR1-LF (PDB 
code 4XES) (ref. 18), with the side chains of L861.54, A1663.49, A215ECL2, and A3607.44 changed to their respective 
wild-type amino acids (A861.54, E1663.49, G215ECL2, V3607.44). The rotamer conformations of F3587.42 were gener-
ated using the program SCREAM (Side Chain Rotamer Energy Analysis Methodology)58.
Molecular dynamics simulations. Preparation of the receptor structures. The molecular dynamics (MD) 
simulations for NTSR1-ELFMD and NTSR1-ELMD in the presence or absence of agonist were started from their 
respective crystal structures [PDB code 4XEE for NTSR1-ELF (ref. 18) and PDB code 5T04 for NTSR1-EL]. In 
all MD simulations, the T4 lysozyme of the crystallization constructs was omitted and the resulting carboxy and 
amino termini were capped at the end of TM5 and the start of TM6. The disordered residues in ICL1 (R91-Q99) 
of the NTSR1-EL crystal structure were homology modelled using Modeler v9.7 (refs 59 and 60). All MD simu-
lations were performed in the presence of the peptide NTS8-13 or in the absence of ligand.
MD simulation protocols. MD simulations were performed with the GROMOS96 force field61 using the soft-
ware package of GROMACS v4.6 (ref. 62) in 2 fs time steps. The NTSR1MD systems were embedded in a hydrated 
palmitoyl-oleoyl-phosphatidyl-choline (POPC) bilayer, and all atoms including receptor, lipid, and waters were 
explicitly presented. For the packing of POPC molecules, we used the inflateGRO (ref. 63) packing package in 
GROMACS. All systems were first equilibrated using 200 ps of constant volume and temperature (NVT) ensem-
ble at 310 K. Then, the systems were equilibrated in the constant pressure and temperature (NPT) ensemble using 
gradually reduced harmonic position restraints from 5 to 1 kcal/mol/Å2 applied to all heavy atoms of the protein 
and peptide ligand NTS8-13 during each of 5 ns. In the final NPT equilibration run, all positional restraints were 
released and run for 10 ns. Production simulations were initiated from the final snapshot of the equilibration run. 
After NVT equilibration followed by stepwise NPT equilibration, we performed five different production runs 
with different initial velocities, with each run up to 100 ns.
Analysis protocols. Calculation of energy contribution. The energy contributions were calculated from the 
non-bonded potential energy including Coulombic and Lennard-Jones terms over all MD ensemble trajectories. 
The components of all energy contributions consisted of the stability of the receptor and the interactions of pro-
tein/ligand, protein/POPC, and protein/waters.
Trajectory analysis. We analysed all 500 ns trajectories from MD simulations by GROMACS analysis tools and 
Python/Tcl scripting as needed. Visual Molecular Dynamics (VMD) and affiliated Tcl script were used for the 
visualization and structural conformation analysis of the MD trajectories. For the interhelical hydrogen bond 
(IHB) and hydrophobic (interhelical van der Waals, IvdW) interactions over the whole trajectories, the g_hbond 
and g_contact tools of GROMACS were used, respectively. To obtain a stable interaction of more than 50% of 
duration during 500 ns simulations, contactFreq of the Tcl script was used. To investigate the presence of water in 
the sodium-binding pocket of NTSR1MD, we used the contacts_water Tcl script for calculating the average number 
of water molecules within 3 Å of each chosen residue in the receptor.
Selection of representative structures. We first clustered the conformations in the MD trajectories by their root 
mean square deviation (RMSD) in coordinates of the main chain atoms in the transmembrane helices, using the 
g_cluster module in GROMACS with gromos clustering algorithm. An RMSD cut-off of 1.5 Å was used on the MD 
trajectories containing snapshots taken every 50 ps. Only main chain atoms of transmembrane helices were con-
sidered in the RMSD-clustering to reduce noise generated by the flexible loops. The representative structure was 
calculated as the frame that has the smallest RSMD to the center of the most populated conformational cluster.
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